# Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

> **NCT05386823** · PHASE1 · COMPLETED · sponsor: **HighField Biopharmaceuticals Corporation** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HF1K16
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05386823
- **Lead sponsor:** HighField Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-20
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-08-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386823, "Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05386823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*